Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Guihua Wang was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Mar 27
China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 28, 2026 China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 28, 2026. Announcement • Mar 17
China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026 China Shineway Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026 Announcement • Aug 18
China Shineway Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 27, 2025 China Shineway Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 27, 2025 Announcement • Mar 18
China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 China Shineway Pharmaceutical Group Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €1.03, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past three years. Reported Earnings • Sep 01
First half 2024 earnings released: EPS: CN¥0.83 (vs CN¥0.65 in 1H 2023) First half 2024 results: EPS: CN¥0.83 (up from CN¥0.65 in 1H 2023). Revenue: CN¥2.09b (down 13% from 1H 2023). Net income: CN¥626.5m (up 28% from 1H 2023). Profit margin: 30% (up from 21% in 1H 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Aug 29
China Shineway Pharmaceutical Group Limited Announces Second Interim Dividend in Respect of the Fiscal Year Ending December 31, 2024, Payable on September 27, 2024 China Shineway Pharmaceutical Group Limited announces Second interim dividend of RMB 0.11 per share in respect of the fiscal year ending December 31, 2024. Ex-dividend date is September 10, 2024. Record date is September 13, 2024 and payment date is September 27, 2024. Announcement • Aug 19
China Shineway Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 29, 2024 China Shineway Pharmaceutical Group Limited announced that they will report first half, 2024 results on Aug 29, 2024 Reported Earnings • Apr 30
Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022) Full year 2023 results: EPS: CN¥1.28 (up from CN¥0.96 in FY 2022). Revenue: CN¥4.52b (up 14% from FY 2022). Net income: CN¥969.5m (up 34% from FY 2022). Profit margin: 22% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Products in clinical trials Phase III: 3 Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Apr 22
Upcoming dividend of HK$0.46 per share Eligible shareholders must have bought the stock before 29 April 2024. Payment date: 17 May 2024. Trailing yield: 6.1%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.4%). Reported Earnings • Mar 29
Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022) Full year 2023 results: EPS: CN¥1.28 (up from CN¥0.96 in FY 2022). Revenue: CN¥4.52b (up 14% from FY 2022). Net income: CN¥969.5m (up 34% from FY 2022). Profit margin: 22% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Announcement • Mar 19
China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 China Shineway Pharmaceutical Group Limited announced that they will report fiscal year 2023 results on Mar 28, 2024 Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €1.20, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 165% over the past three years. Announcement • Nov 01
China Shineway Pharmaceutical Group Limited Announces Resignation of Liu Tiejun as Executive Director, Effective 1 November 2023 The board of directors of China Shineway Pharmaceutical Group Limited announced that Mr. Liu Tiejun ("Mr. Liu") has tendered his resignation as an executive director of the Company with effect from 1 November 2023 in order to devote more time to focus on his role as a vice president of Shineway Pharmaceutical Group Limited (an indirect wholly-owned subsidiary of the Company). Upcoming Dividend • Sep 05
Upcoming dividend of HK$0.12 per share at 5.9% yield Eligible shareholders must have bought the stock before 12 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 5.9%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.6%). Reported Earnings • Sep 01
First half 2023 earnings released: EPS: CN¥0.65 (vs CN¥0.44 in 1H 2022) First half 2023 results: EPS: CN¥0.65 (up from CN¥0.44 in 1H 2022). Revenue: CN¥2.40b (up 32% from 1H 2022). Net income: CN¥491.5m (up 48% from 1H 2022). Profit margin: 21% (up from 18% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Aug 31
China Shineway Pharmaceutical Group Limited Proposes Second Interim Dividend in Respect of the Fiscal Year 2023, Payable on 29 September 2023 China Shineway Pharmaceutical Group Limited Proposed Second interim dividend in respect of the fiscal year 2023 of HKD 0.11 per share. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date Is 29 September 2023. Announcement • Aug 18
China Shineway Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 30, 2023 China Shineway Pharmaceutical Group Limited announced that they will report first half, 2023 results on Aug 30, 2023 Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €1.08, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 21x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 126% over the past three years. Reported Earnings • May 03
Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.74 in FY 2021) Full year 2022 results: EPS: CN¥0.96 (up from CN¥0.74 in FY 2021). Revenue: CN¥3.95b (up 23% from FY 2021). Net income: CN¥722.8m (up 30% from FY 2021). Profit margin: 18% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Products in clinical trials Phase III: 3 Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 13% per year. Upcoming Dividend • Apr 21
Upcoming dividend of HK$0.35 per share at 5.6% yield Eligible shareholders must have bought the stock before 28 April 2023. Payment date: 17 May 2023. Trailing yield: 5.6%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (2.5%). Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.74 in FY 2021) Full year 2022 results: EPS: CN¥0.96 (up from CN¥0.74 in FY 2021). Revenue: CN¥3.95b (up 23% from FY 2021). Net income: CN¥722.8m (up 30% from FY 2021). Profit margin: 18% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Products in clinical trials Phase III: 3 Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Yat On Yew was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 01
China Shineway Pharmaceutical Group Limited Announces Board Changes China Shineway Pharmaceutical Group Limited announced that Mr. Liu Tiejun ("Mr. Liu") has been appointed as executive director of the Company with effect from 1 November 2022. Mr. Liu, aged 48, joined the Group in 1999 and was appointed as vice president of Shineway Pharmaceutical Group Limited ("Shineway Pharmaceutical") (an indirect wholly-owned subsidiary of the Company) on 16 May 2013. Mr. Liu is qualified as a senior engineer and is a certified pharmacist. He graduated from Hebei Medical University in 1999 with a bachelor's degree in pharmacy. Mr. Liu is a member of the China Association of Chinese Medicine (Chinese Medicine Branch) and a deputy director of the National and Local United Engineering Laboratory for the Development Technology of New Chinese Medicine Injection. He has received an award of "Model Worker of Hebei Province" by the People's Government of Hebei Province. Mr. Liu is currently the rotating president and the legal representative of Shineway Pharmaceutical, being responsible for overseeing the Group's production technology management with more than 20 years of experience. The Board also announced that Mr. Chen Zhong ("Mr. Chen") has tendered his resignation as an executive director of the Company with effect from 1 November 2022, due to his intention to devote more time to pursue his personal interests. Announcement • Oct 01
China Shineway Pharmaceutical Group Limited Announces Board and Committee Changes China Shineway Pharmaceutical Group Limited announce that Mr. Yew Yat On ("Mr. Yew") has been appointed as independent non-executive director of the Company with effect from 1 October 2022. Mr. Yew, aged 51, has near 30 years of experience in investment banking and finance. He held various senior positions in several international, Hong Kong and China investment banks and handled a number of initial public offering and merger and acquisition deals. He is the founder and managing director of Alliance Capital Partners Limited, a leading boutique corporate finance house carrying Type 1 and Type 6 regulated activities under the Securities and Futures Ordinance. Mr. Yew holds an Executive Diploma in Organization Leadership from Saïd Business School, University of Oxford, and obtained a Master of Science degree in Investment Management from The Hong Kong University of Science and Technology, and a Bachelor of Arts degree from The University of Hong Kong. Mr. Yew is a chartered financial analyst. Mr. Yew did not hold any directorships in the last three years in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas. As at the date of this announcement, Mr. Yew (i) does not hold any position with the Company or other members of the Group; (ii) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company; and (iii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The Board hereby announces that with effect from 1 October 2022, Prof. Luo Guoan ("Prof. Luo") will cease to serve as an independent non-executive Director due to personal reason. Prof. Luo has confirmed that he has no disagreement with the Board and that he is not aware of any matters in relation to his cessation as an independent non-executive Director need to be brought to the attention of the shareholders of the Company. The Board would like to express its sincere gratitude to Prof. Luo for his valuable contributions to the Company during his tenure of service. The Board announces that following the above changes, with effect from 1 October 2022: Mr. Yew has been appointed as a member of the audit committee, nomination committee, and corporate social responsibility and sustainability committee of the Company; and rof. Luo has ceased to act as a member of the audit committee, nomination committee, and corporate social responsibility and sustainability committee of the Company. Upcoming Dividend • Sep 06
Upcoming dividend of HK$0.13 per share Eligible shareholders must have bought the stock before 13 September 2022. Payment date: 29 September 2022. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 7.8%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.8%). Reported Earnings • Sep 01
First half 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.41 in 1H 2021) First half 2022 results: EPS: CN¥0.44 (up from CN¥0.41 in 1H 2021). Revenue: CN¥1.82b (up 17% from 1H 2021). Net income: CN¥331.1m (up 7.3% from 1H 2021). Profit margin: 18% (down from 20% in 1H 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 16%, compared to a 6.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Aug 31
China Shineway Pharmaceutical Group Limited Announces Dividend for the Six Months Ended 30 June 2022, Payable on 29 September 2022 China Shineway Pharmaceutical Group Limited announced dividend for the six months ended 30 June 2022 of RMB 0.11 per share. Record date is 16 September 2022. Payment date is 29 September 2022. Ex-dividend date is13 September 2022. Announcement • Aug 19
China Shineway Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 30, 2022 China Shineway Pharmaceutical Group Limited announced that they will report first half, 2022 results on Aug 30, 2022 Reported Earnings • May 02
Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.39 in FY 2020) Full year 2021 results: EPS: CN¥0.74 (up from CN¥0.39 in FY 2020). Revenue: CN¥3.22b (up 21% from FY 2020). Net income: CN¥556.7m (up 89% from FY 2020). Profit margin: 17% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 16%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 4% per year. Upcoming Dividend • Apr 27
Upcoming dividend of HK$0.26 per share Eligible shareholders must have bought the stock before 03 May 2022. Payment date: 18 May 2022. Trailing yield: 7.7%. Within top quartile of German dividend payers (4.0%). Higher than average of industry peers (2.5%). Announcement • Mar 31
China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 27, 2022 China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 27, 2022. Reported Earnings • Mar 30
Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.39 in FY 2020) Full year 2021 results: EPS: CN¥0.74 (up from CN¥0.39 in FY 2020). Revenue: CN¥3.22b (up 21% from FY 2020). Net income: CN¥556.7m (up 89% from FY 2020). Profit margin: 17% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year and the company’s share price has also fallen by 6% per year. Announcement • Mar 30
Shineway Pharmaceutical Group Limited Resolves to Declare Interim Dividend of the Year Ending 31 December 2022, Payable on 18 May 2022 The Board of China Shineway Pharmaceutical Group Limited resolved to declare an interim dividend of RMB 21 cents per share amounting to RMB 158,634,000 in respect of the year ending 31 December 2022 and are calculated on the basis of 827,000,000 shares issued less 71,600,000 shares held for share award scheme as at 31 December 2021, which will be paid on 18 May 2022 to the shareholders whose names appear on the Company's register of members on 6 May 2022. The above interim dividend will be payable in cash in Hong Kong dollars and will be converted from Renminbi at the telegraphic transfer exchange rates quoted by bank at 9:00 a.m. on 29 March 2022 (RMB 1=HKD 1.227). Accordingly, the amount payable on 18 May 2022 will be HKD 0.258 per share. Reported Earnings • Sep 03
First half 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 1H 2020) The company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: CN¥1.55b (up 31% from 1H 2020). Net income: CN¥308.5m (up 22% from 1H 2020). Profit margin: 20% (down from 21% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 8% per year. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥1.05, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 12% over the past three years. Upcoming Dividend • May 27
Upcoming dividend of HK$0.25 per share Eligible shareholders must have bought the stock before 03 June 2021. Payment date: 17 June 2021. Trailing yield: 5.2%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (2.9%). Reported Earnings • Apr 29
Full year 2020 earnings released: EPS CN¥0.39 (vs CN¥0.64 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.66b (down 1.9% from FY 2019). Net income: CN¥295.0m (down 41% from FY 2019). Profit margin: 11% (down from 19% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Announcement • Apr 27
China Shineway Pharmaceutical Group Limited Proposes Final Dividend, Payable on 17 June 2021 China Shineway Pharmaceutical Group Limited announced that as mentioned in the announcement of the Company dated 30 March 2021, the Directors proposed that a final dividend of 21 RMB cents (equivalent to HKD 0.2484 according to the telegraphic transfer exchange rates quoted by the bank at 10:00 a.m. on 30 March 2021 (RMB 1=HKD 1.183)) per share (the ‘Final Dividend’) will be paid on 17 June 2021, to Shareholders whose names appear on the register of members of the Company on 10 June 2021, and the above dividend is subject To Approve the Shareholders at the AGM and compliance with the Companies Law. Reported Earnings • Mar 31
Full year 2020 earnings released: EPS CN¥0.39 (vs CN¥0.64 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.66b (down 1.9% from FY 2019). Net income: CN¥295.0m (down 41% from FY 2019). Profit margin: 11% (down from 19% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Announcement • Mar 19
China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021 China Shineway Pharmaceutical Group Limited announced that they will report fiscal year 2020 results on Mar 30, 2021 Is New 90 Day High Low • Feb 23
New 90-day high: €0.65 The company is up 18% from its price of €0.55 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.16 per share. Is New 90 Day High Low • Jan 23
New 90-day high: €0.60 The company is up 13% from its price of €0.54 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.15 per share. Is New 90 Day High Low • Dec 03
New 90-day high: €0.58 The company is up 5.0% from its price of €0.55 on 04 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.98 per share. Is New 90 Day High Low • Sep 28
New 90-day low: €0.54 The company is down 7.0% from its price of €0.57 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.95 per share. Reported Earnings • Sep 25
First half earnings released Over the last 12 months the company has reported total profits of CN¥469.2m, down 13% from the prior year. Total revenue was CN¥2.53b over the last 12 months, down 4.0% from the prior year. Announcement • Aug 18
China Shineway Pharmaceutical Group Limited to Report First Half, 2020 Results on Aug 28, 2020 China Shineway Pharmaceutical Group Limited announced that they will report first half, 2020 results on Aug 28, 2020 